Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Mirum Pharmaceuticals' MIRM.O drug to treat a type of rare disorder, which affects the body's ability to metabolize fats known as cholesterol.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
((Sriparna.Roy@thomsonreuters.com))